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Summary
Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality worldwide.
Genetic risk loci provide novel insights into disease pathogenesis. To broaden COPD genetic risk loci
discovery and identify cell type and phenotype associations, we performed a genome-wide association
study in 35,735 cases and 222,076 controls from the UK Biobank and additional studies from the
International COPD Genetics Consortium. We identified 82 loci with P value < 5x10-8; 47 were previously
described in association with either COPD or population-based lung function. Of the remaining 35 novel
loci, 13 were associated with lung function in 79,055 individuals from the SpiroMeta consortium. Using
gene expression and regulation data, we identified enrichment for loci in lung tissue, smooth muscle
and several lung cell types. We found 9 shared genomic regions between COPD and asthma and 5
between COPD and pulmonary fibrosis. COPD genetic risk loci clustered into groups of quantitative
imaging features and comorbidity associations. Our analyses provide further support to the genetic
susceptibility and heterogeneity of COPD.
Background
Chronic obstructive pulmonary disease (COPD) is a disease of enormous and growing global burden1,
ranked third as a global cause of death by the World Health Organization in 20162. Environmental risk
factors, predominately cigarette smoking, account for a large fraction of disease risk, but there is
considerable variability in COPD susceptibility among individuals with similar smoking exposure. Studies
in families and in populations demonstrate that genetic factors account for a substantial fraction of
disease susceptibility. Similar to other adult-onset complex diseases, common variants likely account for
the majority of population genetic susceptibility3,4. Our previous efforts identified 22 genome-wide
significant loci5. Expanding the number of loci can lead to novel disease pathogenesis insights, not only
through discovery of novel biology6,7, but also through informing more global insights -- such as
functional links between loci, and specific cell-types and phenotypes driving COPD genetic risk5.
We performed a genome-wide association study combining previously described studies from the
International COPD Genetics Consortium (ICGC) with additional subjects from the UK Biobank8, a
population-based study of several hundred thousand subjects with lung function and cigarette smoking
assessment. We determined, through bioinformatic and computational analysis, the likely set of
variants, genes, cell types, and biologic pathways implicated by these associations. Finally, we assessed
our genetic findings for relevance to COPD-specific, respiratory, and other phenotypes.
Results
Genome-wide association study of COPD
We included a total of 257,811 individuals from 25 studies in the analysis, including studies from
International COPD Genetics Consortium and UK Biobank (Figure 1). We defined COPD based on pre-
bronchodilator spirometry according to modified Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria for moderate to very severe airflow limitation9, as done previously5. This definition
resulted in 35,735 cases and 222,076 controls (Supplementary Table 1). We tested association of COPD
and 6,224,355 variants in a meta-analysis of 25 studies using a fixed-effects model. We found no
evidence of confounding by population substructure using linkage disequilibrium score regression (LDSC)
intercept (1.0377, s.e. 0.0094).
We identified 82 loci (defined using 2-Mb windows) at genome-wide significance (P < 5 x 10-8) (Figures 1
and 2; and Supplementary Figures 1 and 2). Forty-seven of 82 loci were previously described as
genome-wide significant in COPD5,10 or lung function11–19 (Supplementary Table 2), leaving 35 novel loci
(Table 1). We then sought to replicate these loci. Given the strong genetic correlation between
population-based lung function and COPD, we tested the lead variant at each locus for association with
FEV1 or FEV1/FVC in 79,055 individuals from SpiroMeta20 (Supplementary Table 3). We identified 13 loci
- C1orf87, DENND2D, DDX1, SLMAP, BTC, FGF18, CITED2, ITGB8, STN1, ARNTL, SERP2, DTWD1, and
ADAMTSL3 – that replicated using a Bonferroni correction for a one-sided P < 0.05/35; Table 1).
Although not meeting the strict Bonferroni threshold, additional 14 novel loci were nominally significant
in SpiroMeta (consistent direction of effect and one-sided P < 0.05): ASAP2, EML4, VGLL4, ADCY5,
HSPA4, CCDC69, RREB1, ID4, IER3, RFX6, MFHAS1, COL15A1, TEPP, and THRA (Table 1), and all 82 loci
showed consistent direction of effect with either FEV1 or FEV1/FVC ratio in SpiroMeta (Table 1 and
Supplementary Table 2). We note that 9 of our 35 novel loci were recently described in a
contemporaneous analysis of lung function in UK Biobank20. None of the novel loci appeared to be
explained by cigarette smoking, and variant effect sizes in ever- and never-smokers and including and
excluding self-reported asthmatics were similar (Supplementary Results). In addition, we found no
significant differences in variant effects by sex (Supplementary Results). Including all 82 genome-wide
significant variants, we explain up to 7.0% of the phenotypic variance in liability scale, using a 10%
prevalence of COPD, and acknowledging that these effects are likely overestimated in the discovery
sample. This represents a 48% increase in COPD phenotypic variance explained by genetic loci compared
to the 4.7% explained by 22 loci reported in a recent GWAS of COPD5.
Identification of secondary association signals
We used approximate conditional and joint analysis to find secondary signals at each of the 82 genome-
wide significant loci. We found 82 secondary signals at 50 loci, resulting in a total of 164 independent
associations in 82 loci (Supplementary Table 4). Of 50 loci containing secondary associations, 33 were at
loci previously described for COPD or lung function, and 6 at Bonferroni-replicated novel loci. Of 82
secondary associations, 20 reached genome-wide significance (P < 5 x 10-8) (Supplementary Table 4). Of
61 novel (not previously described in COPD or lung function) independent associations, 21 reached a
region-wise Bonferroni-corrected threshold (one-sided P < 0.05/novel independent association(s) in
each locus) in unconditioned associations from SpiroMeta (Methods and Supplementary Table 4).
Tissue and specific cell types
In determining the tissue in which COPD genetic variants function to increase COPD risk, lung is the
obvious tissue to consider. However, COPD is a systemic disease21,22 and within the lung, which cell-
types collectively contribute to disease pathogenesis is largely unknown. Furthermore, available
databases often include cell types (e.g. smooth muscle) from other organs (e.g. the gastrointestinal
tract). To identify putative causal tissues and cell types, we assessed the heritability enrichment in
integrated genome annotations at the single tissue level23 and tissue-specific epigenomic marks24. Lung
tissue showed the most significant enrichment (enrichment=9.25, P=1.36 x 10-9), as previously
described, though significant enrichment was also seen in heart (enrichment=6.85, P=3.83 x 10-8) and
the gastrointestinal (GI) tract (enrichment=5.53, P=6.45 x 10-11). In an analysis of enriched epigenomic
marks, the most significant enrichment was in fetal lung and GI smooth muscle DNase hypersensitivity
sites (DHS) (P= 6.75 x 10-8) and H3K4me1 (P= 7.31 x 10-7) (Supplementary Table 5). To identify the
source of association within lung tissue, we tested for heritability enrichment using single-cell chromatin
accessibility25 (ATAC-Seq) and gene expression (RNA-Seq) from human26,27 and murine28 lung
(Supplementary Table 5). Using LD score regression in murine ATAC-Seq data, we found enrichment of
chromatin accessibility in several cell types, including endothelial cells (most significant), type 1, and
type 2 alveolar cells (the latter among the highest fold-enrichment [Supplementary Table 5a]). Results
were varied using LD score regression24 or SNPsea29 on single-cell RNA-Seq, with nominal P-values for
genes expressed in type 2 alveolar cells, basal-like cells, club cells, fibroblasts and smooth muscle cells
(Supplementary Tables 5b and c).
Fine-mapping of associated loci
To identify the most likely causal variants at each locus, we performed fine mapping using Bayesian
credible sets30. Including 160 potential primary and secondary association signals (excluding four
variants in the major histocompatibility complex [MHC] region), 61 independent signals had a 99%
credible set with fewer than 50 variants; 34 signals had credible sets with fewer than 20 variants
(Supplementary Figure 3). Eighteen loci had a single variant with a posterior probability of driving
association (PPA) greater than 60% including the NPNT (4q24) locus, where the association could be
fine-mapped to a single intronic variant, rs34712979 (see Supplementary Results and Supplementary
Table 6). Most sets included variants that overlapped genic enhancers of lung-related cell types (e.g.,
fetal lung fibroblasts, fetal lung, and adult lung fibroblasts) and were predicted to alter transcription
binding motifs (Supplementary Table 6). Of 61 credible sets with fewer than 50 variants, eight sets
contained at least one deleterious variant. These deleterious variants included 1) missense variants
affecting TNS1, RIN3, GPR126, ADAM19, ATP13A2, BTC, and CRLF3; and 2) a splice donor variant
affecting a lincRNA - AP003059.2.
Candidate target genes
In most cases, the closest gene to a lead SNP will not be the gene most likely to be the causal or effector
gene of disease-associated variants31–33. Thus, to identify the potential effector (‘target’) genes
underlying these genetic associations, we integrated additional molecular information including gene
expression; gene regulation (open chromatin and methylation data), chromatin interaction, co-
regulation of gene expression with gene sets and coding variant data (Methods and Figure 3).
At 82 loci, 472 genes within +/- 1 Mb of top associated variants were implicated by analysis of least one
dataset; 106 genes were implicated by lung gene expression, and an additional 50 genes by >= 2 other
datasets (methylation, chromatin interaction, open chromatin regions, similarity in gene sets or
deleterious coding variants [Figure 3]), for a total of 156 genes meeting more stringent criteria.
Excluding loci in the MHC region, the median number of potentially implicated genes per locus was four,
with a maximum of 17 genes (7q22.1 and 17q21.1). The median distance of implicated genes to top
associated variants was 346 Kb. Among 82 loci, 60 loci (73%) included the nearest gene. We identified
20 genes with supportive evidence from exome sequencing data. Two genes (ADAM19 and ADAMTSL3)
were implicated by five datasets (Figure 3) and another two (EML4 and RIN3) were implicated by four
datasets. A summary of all genes implicated using these approaches is included in Supplementary Table
7.
Associated pathways
To gain further functional insight of associated genetic loci, we performed gene-set enrichment analysis
using DEPICT34. Among 165 enriched gene sets at FDR < 5%, 44% of them were related to the
developmental process term, with nominal P for lung development of 1.02 x 10-6; significant sub-terms
included lung alveolus development (P= 0.0003) and lung morphogenesis (P= 0.0005). We also found
enrichment of extracellular matrix -related pathways including laminin binding, integrin binding,
mesenchyme development, cell-matrix adhesion, and actin filament bundles. Additional pathways of
note included histone deacetylase binding, the Wnt receptor signaling pathway, SMAD binding, the
MAPK cascade, and the transmembrane receptor protein serine/threonine kinase signaling pathway.
Full enrichment analysis results including the top genes for each DEPICT gene set are shown in
Supplementary Table 8.
Identification of drug targets
GWAS is also useful for identifying drug targets either at the individual gene17,39,40 or genome-wide
level41,42. Of 482 candidate target genes, 60 genes could be targeted by at least one approved or in-
development drug, totaling 428 drugs with 144 different modes of action (Supplementary Table 13).
Druggable targets at novel loci for COPD and lung function included ABHD6, CDKL2, GSTO2, KCNC4,
PDHB, SLK, and TRPM7. We also identified drugs for repositioning in COPD using transcriptome-wide
associations and drug-induced gene expression signatures (Supplementary Results).
Phenotypic effects of known and novel associations for COPD
To characterize the phenotypic effects of 82 genome-wide significant loci, we performed a phenome-
wide association analysis within the deeply phenotyped COPDGene study (Methods). We assessed for
common patterns of phenotype associations for the 82 loci by using hierarchical clustering across scaled
Z scores of phenotype-variant associations. We identified two clusters of variants differentially
associated with two sets of phenotypes (Supplementary Figure 4). As these two variant-phenotype
clusters appeared to be driven by computed tomography (CT) imaging features, we repeated variant
clustering limited to quantitative CT imaging features. We again found two clusters of variants,
differentiated by association with quantitative emphysema, emphysema distribution, gas trapping, and
airway phenotypes (Figure 4a). Additionally, we evaluated the association of the 82 genome-wide
significant variants in a prior GWAS of emphysema and airway quantitative CT features35
(Supplementary Table 9).
We also examined all genome-wide significant loci in the NHGRI-EBI GWAS Catalog36 (Supplementary
Figure 5 and Supplementary Table 10) and looked for trait-associated variants in linkage disequilibrium
(r2 > 0.2) with our lead COPD-associated variants. Many variants were associated with anthropometric
measures including height and body mass index (BMI), measurements on blood cells (red and white
cells), and cancers. COPD is well known to have many common comorbidities, such as coronary artery
disease (CAD), type 2 diabetes mellitus (T2D), osteoporosis, and lung cancer. Of these diseases and 13
additional traits, we confirmed previously reported overall genetic correlation (using linkage
disequilibrium score regression) of COPD with lung function, asthma, and height, and found evidence of
modest correlation between COPD and lung cancer (Supplementary Results). However, at individual
loci, and using more stringent linkage disequilibrium (r2 > 0.6), we found evidence of shared risk factors
for these comorbid diseases and COPD including a genome-wide significant variant near PABPC4
associated with T2D, four variants with CAD (near CFDP1, DMWD, STN1, and TNS1), and a variant near
SPPL2C with bone density (Figure 4b).
Identification of loci overlapping with asthma and pulmonary fibrosis
Based on our previous identification of genetic overlap of COPD with asthma, and COPD with pulmonary
fibrosis, we examined loci for specific overlap with these two diseases. In asthma, we noted an r2 > 0.2
with one of our variants and previously reported variants at ID2, ZBTB38, C5orf56, MICA, AGER, HLA-
DQB1, ITGB8, CLEC16A, and THRA. In pulmonary fibrosis, in addition to our previously described overlap
at FAM13A, DSP, and 17q21, we noted overlapping associations at ZKSCAN1 and STN1 (Supplementary
Table 11). To more closely examine overlap, we applied a Bayesian method (gwas-pw) of COPD
associations from our current GWAS with previous GWASs of asthma (limited to those of European
ancestry) and pulmonary fibrosis37,38. To mitigate the results of including asthma among our COPD cases,
we performed analysis for overlap with asthma removing self-reported asthmatics from UK Biobank for
this analysis (Methods). We identified 14 shared genome segments (posterior probability > 70%), 9 with
asthma and 5 with pulmonary fibrosis (Figure 4c and Supplementary Table 12). In addition to the three
segments shared with pulmonary fibrosis identified in the previous study5 (FAM13A, DSP, and the 17q21
locus, here CRHR1), we identified two new segments including loci near ZKSCAN1 and STN1 (formerly
known as OBFC1). Shared variants between COPD and pulmonary fibrosis all had an opposite effect (i.e.,
increasing risk for COPD but protective for pulmonary fibrosis). In asthma, we identified five shared
segments in the 6p21-22 regions, as well as ADAM19, ARMC2, ELAVL2, and STAT6. With the exception
of STAT6, overlapping variants showed the same direction of effect.
Discussion
Genetic factors play an important role in COPD susceptibility. We examined genetic risk of COPD in a
genome-wide association study of 35,735 cases and 222,076 controls. We identified 82 genome-wide
significant loci for COPD, of which 47 were previously identified in genome-wide association studies of
COPD or population-based lung function. Of 35 loci not previously described, 13 replicated in an
independent study of population-based lung function. We used several data sources to attempt to
assign causal genes at each locus, identifying 156 genes at 82 loci that were supported by either gene
expression or a combination of at least 2 other data sources. Our results identify specific genes, cell
types, and biologic pathways for targeted study and also suggest a genetic basis for the clinical
heterogeneity seen in COPD.
Our study supports the role of early life events in the risk of COPD. Gene set enrichment analysis
identified developmental pathways both specific to the lung (e.g., lung morphogenesis and lung alveolar
development) and related to the lung (e.g., the canonical Wnt receptor43,44, the MAPK/ERK, and the
nerve growth factor receptor signaling pathways). We also confirmed enrichment of heritability in
epigenomic marks of fetal lung. Our findings are consistent with epidemiologic studies demonstrating
that a substantial portion of the risk of COPD may develop in early life: genetic variants may set initial
lung function45 and patterns of growth45–47. While further work will be needed to confirm the causal
variants and genes affected by our variants, testing the role of these genes in lung development-
relevant murine or ex-vivo models – for example, determining whether the perturbation of these genes
changes proliferation and differentiation of lung epithelial progenitors in induced pluripotent cell-
derived lung alveolar type 2 cells44 – could provide experimental evidence of the role of these genes in
early life susceptibility. Ultimately, the goal of this work would be to identify targets for or subsets of
high risk individuals early in the disease course, or molecular candidates that may affect lung repair and
regeneration48.
Apart from genes related to lung development, our analyses highlighted several genes and pathways
already of interest in COPD therapy (e.g. CHRM3 / acetylcholine receptor inhibitors, the MAPK pathway)
– supporting the role of genetic analyses in finding therapeutic targets17,49 – and newer genes that could
inform future functional studies. We identified interleukin 17 receptor D (IL17RD), as a potential effector
gene at the at 3p14 locus. Numerous studies have examined the role of IL-17A in COPD50, and IL17RD
can differentially regulate pathways employed by IL-17A51 . Chitinase acidic (CHIA) at 1p13.3, which
encodes a protein that degrades chitin52, exhibits lung-specific expression53,54. CHIA variants have been
associated with FEV155, asthma56–59, and acid mammalian chitinase activity58,60. We identified several
potential effector genes related to extracellular matrix, cell adhesion, cell-cell interactions, and elastin-
associated microfibrils61–63, some of which have been previously identified in studies of lung function14.
These include integrin family members that mediate cell-matrix communication (e.g., ITGA1, ITGA2,
ITGA864–66), an integrin ligand encoding gene (NPNT67), and genes encoding matrix proteins (e.g., MFAP2
and ADAMTSL3). ADAMTSL3 plays a role in cell-matrix interactions related to the assembly of fibrillin
and microfibril biogenesis68–70 and of our candidate effector genes was supported by the greatest
number of bioinformatic analyses. Recombinant forms of other ADAMTS-like proteins demonstrate
experimental evidence of promoting and enhancing fibrillin and microfibril deposition and assembly71,72.
ADAMTSL3 may play a role in preventing emphysematous destruction of lung tissue by ADAMTS in
COPD.
In addition to identifying the effector gene, knowing the effector cell type is critical for functional
studies. We identified an overall enrichment of epigenomic marks in lung tissue and smooth muscle
(also identified in studies of lung function15). This latter association was found in gastrointestinal tissue
cell types; respiratory smooth muscle is absent in the analyzed datasets. We also performed analyses of
single-cell data in an attempt to identify the specific lung cell types in which our top variants are
potentially functioning. We found evidence for enrichment of several cell types, including but not
limited to endothelial cells, alveolar type 2 cells, and basal-like cells. Each of these cell types has been
postulated to have a role in the development of COPD73–75, and our data is consistent with the likely
heterogeneity of lung cell types contributing to COPD susceptibility. The lung is comprised at least 40
different resident cell types76, most of which are not distinctly represented in these datasets. Thus, while
our findings support the investigation of specific cell types for further functional studies, they also
highlight the need for profiling of lung-relevant cell types and loci-specific analyses.
Characterization of functional variant effects could lead to better disease subtyping and more targeted
therapy for COPD. Cluster analysis on hundreds of COPD-associated features in the more extensively
phenotyped COPDGene cohort revealed heterogeneous effects of genetic variants on COPD-related
phenotypes, including computed tomography (CT) measurements of airway abnormalities and
emphysema – well-described sources of heterogeneity in COPD77–79. Analyzing hundreds of
diseases/traits in GWAS Catalog, we identified overlapping associations with various diseases/traits in
multiple organ systems, comorbidities such as coronary artery disease, bone mineral density, and type 2
diabetes mellitus (T2D). The COPD-associated PABPC4 locus was associated with T2D80 and C-reactive
protein (CRP) level81. Although a causal gene in this locus and its contribution to COPD is unknown, its
association with T2D may suggest a shared disease pathway and drug targets. Together, the
identification of variable COPD risk loci associations with sub-phenotypes and other diseases83,84 may
have potential for more nuanced approaches to therapy for COPD. Overall, our phenotype, gene, and
pathway analyses illustrate the utility of both searching for enrichment of genetic signals overall, and
performing a more detailed identification of the effects of individual variants or groups of variants.
We performed additional specific analysis in two diseases that overlap with COPD, asthma and
pulmonary fibrosis. While a genome-wide genetic correlation of COPD and asthma has been previously
described5, our analysis is the first to identify specific shared genetic segments between asthma and
COPD. While the effects at most of these shared segments were concordant in direction, one of the
segments of particular interest was near STAT6, which had opposite directions of effect in the two
diseases. STAT6 plays a role in T helper (Th) type 2-dependent inflammation, and is activated by
interleukin-4 and interleukin-13 (IL-4 and IL-13)85. IL-13, in turn, has been found to be increased in
asthmatic airways86 but decreased in severe emphysema87. In pulmonary fibrosis, variants at all
overlapping loci have an opposite direction of effect compared to COPD5. These effects raise the
possibility that specific therapies for one disease could increase the risk of the other disease, which may
be worth evaluating in treatment trials. The reasons why genetic effects are divergent between COPD
and fibrosis are unclear, but these identified opposite effects could point to molecular switches that
influence why some smokers develop emphysema while others develop pulmonary fibrosis. While
pulmonary fibrosis is an uncommon disease and specifically excluded in several of our COPD case-
control cohorts, interstitial lung abnormalities are increasingly being recognized as a potential precursor
to fibrosis and an inverse relationship between these abnormalities and emphysema has been
previously identified88. Mechanistically, some have hypothesized that the divergent derangement of
Wnt and Notch signaling pathways89 and mesenchymal cell fate90 may be responsible for the distinct
development of these two diseases. We also describe an overlapping region at the STN1 (previously
known as OBFC1) locus. STN1 plays a role in telomere maintenance91; shortened telomeres have been
observed in both COPD and IPF92,93, and rare genetic variants in the telomerase pathway have been
implicated in both pulmonary fibrosis and emphysema – albeit with concordant effects on either
disease94.
While our study is the largest genome-wide association study of COPD, individuals meeting our criteria
for COPD in the UK Biobank may be different from other studies, especially for smoking history. We used
the same definition of COPD as in our prior analysis5, which included non-smokers. Our use of pre-
bronchodilator spirometry to define COPD (allowing us to maximize sample size) as well as population-
based lung function for replication could bias our findings against variants that are only associated with
more severe forms of COPD. We did not exclude other causes of airway obstruction such as asthma,
noting that asthma frequently overlaps with and is misdiagnosed in COPD95. We performed several
additional analyses to determine whether our results were driven by, or markedly different, by smoking
status, asthma, or use of pre- instead of post-bronchodilator spirometry to define COPD. The results of
these additional analyses did not indicate a substantial impact of these factors on our overall findings,
and together with prior analyses5,15, suggest that bias due to these factors is likely small. However, our
study was not designed to identify differences between subgroups, and we cannot rule out a role for
studying more severe disease or disease subtypes. We note that the alpha-1 antitrypsin locus
(SERPINA1) was identified as genome-wide significant in smaller studies of emphysema and in smokers
with severe COPD96. In the current study, the association of the PiZ allele had P = 2.2 x 10-5 using
moderate-to-severe cases (FEV1 < 80% predicted), and a smaller P-value (1.4 x 10-6) in severe cases (FEV1
< 50% predicted) despite a smaller sample size, a phenomenom we have previously described10. Thus,
despite the strong overlap of COPD with quantitative spirometry, new loci may be identified through
studies of sufficiently large subsets of COPD patients and with more specific and homogeneous COPD
phenotypes. Given suggestive evidence for replication using a related (but not identical) phenotype for
additional novel loci beyond the 13 meeting a Bonferroni-corrected threshold for significance, we chose
to include all loci significant in discovery in subsequent analyses, recognizing that we likely included
some false positive associations. Our study focused on relatively common variants, predominantly in
individuals of European ancestry; more detailed studies of rare variants, the human leukocyte antigen
(HLA) regions, and other ethnicities are warranted, but broader multi-ethnic analyses are limited by the
number of cases in currently available cohorts. Although COPD sex differences have been reported97, we
did not identify significant sex-specific differences in effect sizes of the 82 top variants. Future studies
including more subjects and methodological advances may be needed to elucidate this effect.
The global burden of COPD is increasing. Our work finds a substantial number of new loci for COPD and
uses multiple lines of supportive evidence to identify potential genes and pathways for both existing and
novel loci. Further investigation of the genetic overlap of COPD with other respiratory diseases and the
phenotypic effects of top loci finds new shared loci for asthma and idiopathic pulmonary fibrosis and
suggests heterogeneity across COPD-associated loci. Together, these insights provide multiple new
avenues for investigation of the underlying biology and the potential therapeutics in this deadly disease.
Methods
Study populations
The UK Biobank is a population-based cohort consisting of 502,682 individuals8. To determine lung
function, we used measures of forced expiratory volume in 1 second (FEV1) and forced vital capacity
(FVC) derived from the spirometry blow volume-time series data, subjected to additional quality control
based on ATS/ERS criteria98 (Supplementary Methods). As in our previous study5, we defined COPD
using pre-bronchodilator spirometry according to modified Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria for moderate to very severe airflow limitation9: FEV1 less than 80% of predicted
value (using reference equations from Hankinson et al.99), and the ratio between FEV1 and FVC less than
0.7. Consistent with our previous analyses and enrollment criteria for COPD case-control datasets100, we
did not exclude individuals based on self-reported asthma. Genotyping was performed using Axiom UK
BiLEVE array and Axiom Biobank array (Affymetrix, Santa Clara, California, USA) and imputed to the
Haplotype Reference Consortium (HRC) version 1.1 panel101.
We invited participants in the prior International COPD Genetics Consortium (ICGC) COPD genome-wide
association study to provide case-control association results (with the exception of the 1958 British Birth
Cohort, to avoid overlapping samples with the replication sample). ICGC cohorts performed case-control
association analysis based on pre-bronchodilator measurements of FEV1 and FEV1/FVC, and cases were
identified using modified GOLD criteria, as above. Studies were imputed to 1000 Genomes reference
panels. Detailed cohort descriptions and cohort-specific methods have been previously published5
(Supplementary Methods).
Based on the strong genetic overlap of lung function and COPD5, we performed lookups of select
significant variants for FEV1 and FEV1/FVC in the SpiroMeta consortium meta-analysis20. Briefly,
SpiroMeta comprised of a total of 79,055 individuals from 22 studies imputed to either the 1000
Genomes Project Phase 1 reference panel (13 studies) or the HRC (9 studies). Each study performed
linear regression adjusting for age, age2, sex, and height, using rank-based inverse normal transforms,
adjusting for population substructure using principal components or linear mixed models, and
performing separate analyses for ever- and never- smokers or using a covariate for smoking (for studies
of related subjects). Genomic control was applied to individual studies, and results were combined using
a fixed-effects meta-analysis20.
Genome-wide association analysis
In UK Biobank, we performed logistic regression of COPD, adjusting for age, sex, genotyping array,
smoking pack-years, ever smoking status, and principal components of genetic ancestry. Association
analysis was done using PLINK 2.0 alpha102 (downloaded on December 11, 2017) with Firth-fallback
settings, using Firth regression when quasi-complete separation or regular-logistic-regression
convergence failure occurred. We performed a fixed-effects meta-analysis of all ICGC cohorts and UK
Biobank using METAL (version 2010-08-01)103. We assessed population substructure and cryptic
relatedness by linkage disequilibrium (LD) score regression intercept104. We defined a genetic locus using
a 2-Mb window (+/-1 Mb) around a lead variant, with conditional analyses as described below.
To maximize our power to identify existing and discover new loci, we examined all loci at the genome-
wide significance value of P < 5 x 10-8. We first characterized loci as being previously described (evidence
of prior association with lung function11–19,105,106 or COPD5,10,107) or novel. We defined previously reported
signals if they were in the same LD block in Europeans108 and in at least moderate LD (r2 >= 0.2). For
novel loci we attempted replication through association of each lead variant with either FEV1 or
FEV1/FVC ratio in SpiroMeta, using one-sided p values with Bonferroni correction for the number of
novel loci examined. Novel loci failing to meet a Bonferroni-corrected P value were assessed for nominal
significance (one-sided P < 0.05) or directional consistence with FEV1 and FEV1/FVC ratio in SpiroMeta.
Cigarette smoking is the major environmental risk factor for COPD and genetic loci associated with
cigarette smoking have been reported5,109. While we adjusted for cigarette smoking in our analysis, we
further examined these effects by additionally testing for association of each locus with cigarette
smoking and by looking at two separate analyses of ever- and never- smokers in UK Biobank. We tested
for sex-specific genetic effects of genome-wide significant variants via a stratified analysis and
interaction testing, using a 5% Bonferroni-corrected threshold to determine significance
(Supplementary Methods).
Identification of independent associations at genome-wide significant loci
We identified specific independent associations at genome-wide significant loci using GCTA-COJO110.
This method utilizes an approximate conditional and joint analysis approach requiring summary
statistics and representative LD information. As the UK Biobank provided the predominant sample, we
used 10,000 randomly drawn unrelated individuals from this discovery dataset as a LD reference sample.
We scaled genome-wide significance to a 2-Mb region, resulting in a locus-wide significant threshold of
8 x 10-5, or 2 x 10-6 for variants in the major histocompatibility complex (MHC) region (chr6:28477797-
33448354 in hg19111). We created regional association plots via LocusZoom using 1000 Genomes EUR
reference data (Nov2014 release)112.
Identification and prioritization of tissues and cell types, candidate variants, genes, and
pathways
Identification of enriched tissues and specific cell types
We used LD Score Regression (LDSC) to estimate the enrichment of functional annotations113 and
specifically expressed gene regions24 on disease heritability. We utilized LDSC baseline models (e.g.,
conserved region, promoter flanking region), tissue-specific annotations from the Roadmap Epigenomics
Program24, integrated tissue annotations from GenoSkyline23, and cell type-specific chromatin
accessibility data25 (ATAC-Seq). We used four single-cell gene expression (RNA-Seq) datasets to identify
specific cell types (Supplementary Methods), including 1) lung epithelial cells from normal and
pulmonary fibrosis human lung26 (Gene Expression Omnibus [GEO] accession GSE86618), 2) human
induced pluripotent stem cells (iPSCs)-derived putative alveolar type 2 cells27 (GSE96642), 3) mouse
lungs at embryonic day 18.5 (E18.5) and 4) postnatal day 1 (P1) by Whitsett et al. (available at
LungMAP28). We also used SNPsea29 to identify enriched cell types in genome-wide significant loci
(Supplementary Methods). We reported only estimates of coefficients and P values for the Roadmap
annotations and gene expression datasets, as theses analyses used –h2-cts, which does not report fold
enrichment.
Fine-mapping of independent association signals at genome-wide significant loci
We used Bayesian fine-mapping at each locus to identify the credible set: the set of variants with a 99%
probability of containing a causal variant. Briefly, for each genome-wide significant loci we calculated
approximate Bayes factors30 of association. We then selected variants in each locus, so that their
cumulative posterior probability was equal or greater than 0.99 using an unscaled variance. At loci with
multiple independent associations, we used statistics from approximate conditional analysis with GCTA
software on each index variant adjusting for other independent variants in the loci. Otherwise, we used
unconditioned statistics from our meta-analysis. We characterized variant effects in credible sets using
variant annotations from Ensembl Variant Effect Predictor114.
Identification of target genes
We used several computational approaches with corresponding available datasets to identify target
genes in genome-wide significant loci. We used two methods that utilized gene expression data: 1) S-
PrediXcan and 2) DEPICT. We used S-PrediXcan115 to identify genes with genetically regulated expression
associated with COPD. We used data from the Lung-eQTL consortium116,117 (1,038 lung tissue samples)
as an eQTL and gene expression reference database. S-PrediXcan is the extension of PrediXcan118 that
test for association between a trait and imputed gene expression using summary statistics. Here, we
performed S-PrediXcan using models for protein-coding genes +/- 1 Mb from top-associated variants at
genome-wide significant loci. We used DEPICT (Data-driven Expression Prioritized Integration for
Complex Traits)34 to prioritize genes from ‘reconstituted’ gene sets.
We also used additional information on gene regulation, including epigenetic data: 1) regulatory fine
mapping, 2) mQTL, and 3) chromosome conformation capture. We used regulatory fine mapping
(regfm119) to overlap 99% credible interval (CI) variants at each GWAS locus with open chromatin regions
based on DNAse hypersensitivity sites (DHS). DHS cluster accessibility state was then associated with
gene expression levels (for 13,771 genes) from 22 tissues in the Roadmap Epigenomics Project120. Using
both the 99% CI and DHS overlap, as well as the DHS state and transcript level association, regfm
calculates a posterior probability of association of each gene +/- 1 Mb of the lead SNP at each GWAS
locus. We also searched for overlapping methylation quantitative trait loci (mQTL) data from lung tissue,
as recently described121. To determine whether these signals co-localized (rather than being related due
to linkage disequilibrium), we performed colocalization analysis between our GWAS and mQTL in
genome-wide significant loci using eCAVIAR122 (eQTL and GWAS CAusal Variants Identification in
Associated Regions, Supplementary Methods). We also sought information from publicly available
chromosome conformation capture data123. We queried association statistics of chromatin contact (i.e.,
long range chromatin interactions) between top associated variants and gene promoters nearby in a
lung (fetal lung fibroblast cell line (IMR90) and human lung tissue123) using HUGIn124 (Hi-C Unifying
Genomic Interrogator). We retained only the strongest associations (i.e., smallest P value) for each cell
line/primary cell in the analysis.
Finally, we searched for signals from deleterious variants by querying consequences of variants within
99% credible sets containing fewer than 50 variants (Supplementary Methods). We also searched for
rare coding variants, based on exome sequencing results in the COPDGene, Boston Early-Onset COPD,
and International COPD Genetics Network studies, as previously described125. In brief, we performed
exome sequencing on 485 severe COPD cases and 504 smoking resistant controls from the COPDGene
study and 1,554 subjects ascertained through 631 probands with severe COPD from the Boston Early-
Onset COPD study (BEOCOPD) and the ICGN study. We performed single-variant analyses using Firth and
efficient resampling methods (SKAT R package126) for the COPDGene data (case-control) and generalized
linear mixed models (GMMAT) for the BEOCOPD-ICGN data (using lung function). Gene-based analyses
were conducted using burden, SKAT, and SKAT-O tests with asymptotic and efficient resampling
methods (SKAT package) combined with Fisher’s method for the COPDGene data, and using SKAT-O
tests (MONSTER) for the BEOCOPD-ICGN data. Two variant-filtering criteria were considered:
deleterious variants (predicted by FATHMM) with minor allele frequency (MAF) < 0.01, and functional
variants (moderate effect predicted by SNPEff) with MAF < 0.05. We also applied a gene-based
segregation test (GESE) to the ultra-rare (MAF < 0.1%) and loss-of-function variants in the BEOCOPD-
ICGN data on the severe COPD affection status. In gene-based analyses, we combined results from all
methods above and retained only most significant P values for each gene.
For each dataset described above, we used Bonferroni-corrected P values, or a fixed posterior
probability threshold to determine target genes at each locus. We reported protein-coding genes +/-1
Mb from a top associated variant. We restricted our search to genes from the GRCh37 server in
biomaRt114 with updated HUGO Gene Nomenclature Committee (HGNC) names (downloaded from
https://genenames.org on June 7, 2018). For each locus, we used a 5% Bonferroni-corrected threshold
(i.e., P < 0.05 divided by number of genes at that locus) to determine significance for 4 data types: gene
expression data, chromatin conformation capture data, co-regulation of gene expression, and exome
sequencing results. For two remaining datasets, we used a fixed posterior probability (of gene
association with a GWAS locus) threshold of 0.1 for regfm and eCAVIAR. We considered genes that were
implicated by gene expression or >= 2 combination of other datasets (e.g., methylation and chromatin
conformation capture data) as target genes.
Identification of pathways
To identify enriched pathways in COPD-associated loci, we performed gene-set enrichment analysis
using the “reconstituted” genes sets from DEPICT, as described above34. We defined significant gene
sets using false discovery rate (FDR) < 5%.
Effects on COPD-related and other phenotypes
COPD is a complex and heterogeneous disorder, comprised of different biologic processes and specific
phenotypic effects. In addition, many loci discovered by GWAS have pleiotropic effects. To identify these
effects, we performed analyses of a) identification of overlapping genetic loci between related disorders
(asthma and pulmonary fibrosis) b) genetic association studies of our genome-wide significant findings
using COPD-related phenotypes, including a cluster analysis to identify groups of variants that may be
acting via similar mechanisms; c) look up of top variants in prior COPD-related quantitative computed
tomography (CT) imaging feature GWAS, d) look up of associations with other diseases/traits using
GWAS Catalog, and e) estimate the genetic correlation between COPD and other diseases/traits.
To identify overlapping loci between COPD and other respiratory disorders, we used gwas-pw127 to
perform pairwise analysis of GWAS. This method searches for shared genomic segments108 using
adaptive significance threshold, allowing detection of sub genome-wide significant loci. We identified
shared segments or variants using posterior probability of colocalizing greater than 0.7127. We obtained
GWAS summary statistics from two previous studies of pulmonary fibrosis38 and asthma in Europeans37.
For the overlap analysis of COPD with asthma, we examined the influence of the inclusion of individuals
with self-reported asthma on both the overlap of discrete GWAS loci (using gwas-pw) and genome-wide
genetic correlation (using LD score regression) by performing these analyses in the meta-analysis of
ICGC studies and the UK Biobank (with individuals with asthma removed from cases in the latter). To
assess heterogeneous effects of COPD susceptibility loci on COPD-related features (phenotypes), we
evaluated associations of our genome-wide significant SNPs with 121 detailed phenotypes (e.g., lung
function, computed tomography-derived metrics, biomarkers, and comorbidities) available in 6,760
COPDGene non-Hispanic whites. We calculated Z-scores for each SNP-phenotype combination relative
to the COPD risk allele to create a SNP by phenotype Z-score matrix. We tested each COPD-related
phenotype with at least one nominally significant association with one of our genome-wide significant
COPD SNPs, leaving us with 107 phenotypes. We then oriented all Z-scores to be positive (based on sign
of median Z score) in association with each phenotype to avoid clustering based on direction of
association. To avoid clustering phenotypes only by strength of association with SNPs, we scaled Z-
scores within each phenotype by subtracting mean Z-scores and dividing by the standard deviation of Z-
scores within each phenotype. We then scaled Z-scores across SNPs to circumvent clustering of SNPs
according only to relative strength of association with phenotypes. We then performed hierarchical
clustering of the scaled Z-scores of associations between SNPs and phenotypes to identify clusters of
SNPs and phenotypes for all 107 phenotypes as well as in the subset of 26 quantitative imaging
phenotypes. We identified optimal number of clusters using the Calinski index128,129. To identify features
that independently predict cluster membership, we fitted a logistic regression model via penalized
maximum likelihood using the glmnet package130. We determined optimal regularization parameters
using 10-fold cross validation. We further examined top variant associations with COPD-related traits
through a look-up of top variants in a prior GWAS of 12,031 subjects with quantitative emphysema and
airway CT features35. To examine overlap of our COPD results with other traits, we downloaded genome-
wide significant associations from the GWAS Catalog36,131 (P < 5 x 10-8). Between a pair of COPD- and
trait- associated variants within the same LD block in Europeans108, we computed the LD using the
European ancestry panel132 and considered the overlap if variants were in at least in moderate LD (r2 >=
0.2). We estimated genetic correlation between COPD and other diseases/traits using a web engine for
LDSC, LD Hub133. We assessed the results using a 5% Bonferroni-corrected significance level.
Identification of drug targets
We queried our target genes using the Drug Repurposing Hub134, available at https://clue.io. This
resource contains comprehensive annotations of launched drugs, drugs in phases 1-3 of clinical
development, previously approved and preclinical or tool compounds, curated using publicly available
sources (e.g., ChEMBL and Drugbank) and proprietary sources. We performed drug-gene expression
similarity analysis135 (the Query, https://clue.io) using a ranked gene set from a gene-based association
test115 (Supplementary Methods).
Figures
Figure 1 Study design
COPD, chronic obstructive pulmonary disease; FEV1, force expiratory volume in one second; FVC, forced
vital capacity.
Figure 2 Manhattan plot
Loci are labeled with the closest gene to the lead variant. Colors indicates variants at novel loci which
replicated using a Bonferroni-corrected threshold in SpiroMeta (dark blue, one sided P < 0.05/35) and a
nominally significant threshold (light blue, one-sided P < 0.05).
Figure 3 Identification of target genes
(a) Overview of datasets used to identify target genes at genome-wide significant loci (b) Regional
association plots at ADAMTSL3 locus showing GWAS (top), chromatin interaction in lung tissue (middle)
and expression quantitative trait loci (bottom). GREx, Genetically regulated gene expresssion (significant
associations identified by S-PrediXcan); mQTL, methylation quantitative trait loci (colocalized signals
between GWAS and mQTL at posterior probability > 0.1); Cod., Coding associations (significant single
variant or gene-based association tests for deleterious coding variants); Hi-C, significant chromatin
interaction identified in human lung or the IMR90 cell line; DHS, DNase hypersensititvity sites (using
regulatory fine-mapping or regfm, Methods); GSet, target genes identified by DEPICT using
reconstituted gene sets.
Figure 4 Effects on COPD-related and other phenotypes
(a) Heatmap of scaled computed tomography (CT) quantitative imaging associations with the 34
genome-wide significant variants (known and replicated novel associations) with at least nominal
(P<0.05) association with any CT imaging feature in COPDGene non-Hispanic white participants. Red
coloring suggests more positive association with a phenotype and blue suggests less positive association
with a phenotype. Cluster 1 variants are more associated with airway imaging features and Cluster 2
variants are more associated with emphysema imaging features. Variants are referred to by the closest
gene. (b) Overlapping of genome-wide significant loci of COPD and select traits from GWAS Catalog (c)
Genome-wide overlapping results between COPD with pulmonary fibrosis (left) and asthma (right). PRM
emphysema, emphysema quantified by parametric response mapping; UL, upper lobe of the lung; LL,
lower lobe of the lung; Pi10, an airway feature calculated from regressing the square root of the airway
wall area with the airway internal perimeter.
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Table 1 Meta-analysis results showing 35 loci novel for COPD and lung function
(see the Excel file)
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